Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imvotamab in Refractory Idiopathic Inflammatory Myopathies
NCT06524687Phase 1Terminated
- Sponsor
- IGM Biosciences
- Start
- May 2024
- Primary completion
- Jan 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imvotamab in idiopathic inflammatory myopathies (IIM), sponsored by IGM Biosciences. Primary endpoint: Safety and tolerability of imvotamab. Started May 2024; status: terminated.
02
Drugs
imvotamab
03
Conditions
idiopathic inflammatory myopathies (IIM)
Beyond the preview
Go deeper on NCT06524687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06524687.